Evidence map›Paper›PMID 25355869›Full record

ArticleJournal of virology2015

Polyreactivity and autoreactivity among HIV-1 antibodies.

Mengfei Liu, Guang Yang, Kevin Wiehe, Nathan I Nicely, Nathan A Vandergrift, Wes Rountree, Mattia Bonsignori, S Munir Alam, Jingyun Gao, Barton F Haynes and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 127 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
127citing papers in PubMed, 2 pooled it
9.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

127 citing papers in PubMed, 2 syntheses or guidelines pooled it, 159 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

67 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Mengfei LiuSchool of Medicine, Duke University, Durham, North Carolina, USA.
Guang YangDepartment of Immunology, Duke University, Durham, North Carolina, USA.
Kevin WieheHuman Vaccine Institute, Duke University, Durham, North Carolina, USA.
Nathan I NicelyHuman Vaccine Institute, Duke University, Durham, North Carolina, USA.
Nathan A VandergriftHuman Vaccine Institute, Duke University, Durham, North Carolina, USA Department of Medicine, Duke University, Durham, North Carolina, USA.
Wes RountreeHuman Vaccine Institute, Duke University, Durham, North Carolina, USA.
Mattia BonsignoriHuman Vaccine Institute, Duke University, Durham, North Carolina, USA Department of Medicine, Duke University, Durham, North Carolina, USA.
S Munir AlamHuman Vaccine Institute, Duke University, Durham, North Carolina, USA.
Jingyun GaoSchool of Medicine, Duke University, Durham, North Carolina, USA.
Barton F HaynesDepartment of Immunology, Duke University, Durham, North Carolina, USA Human Vaccine Institute, Duke University, Durham, North Carolina, USA Department of Medicine, Duke University, Durham, North Carolina, USA.
Garnett KelsoeDepartment of Immunology, Duke University, Durham, North Carolina, USA Human Vaccine Institute, Duke University, Durham, North Carolina, USA ghkelsoe@duke.edu.
Duke University · US

Funding

Virus biology scientific research support componentUM1AI100645 · NIAID · DUKE UNIVERSITY · PI MONTEFIORI, DAVID C · 2012 to 2018
$204.7M
B-cell Tolerance and Humoral Immunity to HIV-1R01AI081579 · NIAID · DUKE UNIVERSITY · PI KELSOE, GARNETT H · 2009 to 2012
$1.6M
Howard Hughes Medical InstituteNIAID NIH HHS AI 100645NIAID NIH HHS AI 81579NIAID NIH HHS R01 AI081579NIAID NIH HHS UM1 AI100645
6 · The paper itself

Abstract

unlabelledIt is generally acknowledged that human broadly neutralizing antibodies (bNAbs) capable of neutralizing multiple HIV-1 clades are often polyreactive or autoreactive. Whereas polyreactivity or autoreactivity has been proposed to be crucial for neutralization breadth, no systematic, quantitative study of self-reactivity among nonneutralizing HIV-1 Abs (nNAbs) has been performed to determine whether poly- or autoreactivity in bNAbs is a consequence of chronic antigen (Ag) exposure and/or inflammation or a fundamental property of neutralization. Here, we use protein microarrays to assess binding to >9,400 human proteins and find that as a class, bNAbs are significantly more poly- and autoreactive than nNAbs. The poly- and autoreactive property is therefore not due to the infection milieu but rather is associated with neutralization. Our observations are consistent with a role of heteroligation for HIV-1 neutralization and/or structural mimicry of host Ags by conserved HIV-1 neutralization sites. Although bNAbs are more mutated than nNAbs as a group, V(D)J mutation per se does not correlate with poly- and autoreactivity. Infrequent poly- or autoreactivity among nNAbs implies that their dominance in humoral responses is due to the absence of negative control by immune regulation. Interestingly, four of nine bNAbs specific for the HIV-1 CD4 binding site (CD4bs) (VRC01, VRC02, CH106, and CH103) bind human ubiquitin ligase E3A (UBE3A), and UBE3A protein competitively inhibits gp120 binding to the VRC01 bNAb. Among these four bNAbs, avidity for UBE3A was correlated with neutralization breadth. Identification of UBE3A as a self-antigen recognized by CD4bs bNAbs offers a mechanism for the rarity of this bNAb class. IMPORTANCE: Eliciting bNAbs is key for HIV-1 vaccines; most Abs elicited by HIV-1 infection or immunization, however, are strain specific or nonneutralizing, and unsuited for protection. Here, we compare the specificities of bNAbs and nNAbs to demonstrate that bNAbs are significantly more poly- and autoreactive than nNAbs. The strong association of poly- and autoreactivity with bNAbs, but not nNAbs from infected patients, indicates that the infection milieu, chronic inflammation and Ag exposure, CD4 T-cell depletion, etc., alone does not cause poly- and autoreactivity. Instead, these properties are fundamentally linked to neutralization breadth, either by the requirement for heteroligation or the consequence of host mimicry by HIV-1. Indeed, we show that human UBE3A shares an epitope(s) with HIV-1 envelope recognized by four CD4bs bNAbs. The poly- and autoreactivity of bNAbs surely contribute to the rarity of membrane-proximal external region (MPER) and CD4bs bNAbs and identify a roadblock that must be overcome to induce protective vaccines.

Indexed as

AutoantibodiesHIV-1HIV AntibodiesHumansMicroarray AnalysisProtein Array AnalysisProtein BindingAutoantibodiesHIV Antibodies

Identifiers

PMID25355869
PMCPMC4301171
OpenAlexW1980193047

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.